»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ gV\{Qoj
-=)Al^V4T
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 }aC@o v]2
jQIb :\0#
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© TC$)::C1
1.Antigen presenting cell£¨APC£© quGvq"Y>
2.Activation induced cell death£¨AICD£© Sl7x>=
3.Chemokine ]/klKqz
4.Major histocompatibility complex£¨MHC£© rrL
gBeQa
5.immunotolerance F\G-. 1
Ub_!~tb}?
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© `\vqDWh8-
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ 2uln)]
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà ?n0Z4 8%
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ psaPr E
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ a6<UMJ
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã 4
[K"e{W3
>L_nu.x
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© iT2{3t
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ 2 f8\Osn>m
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ )4tOTi[
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ vv
FH (W
SE7mn6,%\
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ w28&qNha
LjEG1$F>
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 z?I"[M
9m+ejTK{U
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ Krw'|<
1.Antigenic determinant C4H$w:bVk
2.IgSF ]H$Trf:L
3.MBL;¾¶ LuE0Hb"S8
4.chemokine z55g'+Kab
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ
epm ~
6.TCR-CD3¸´ºÏÎï v
BLs88
7.FADD£¨Fas-associated protein with death domain£© S\dG>F>S
8.AIDS r"&uW!~0
9.Tumor rejection antigen $No^\.mV
10.AICD \TS.9 >\
eZdFfmYW^R
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ `P/87=h
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© 'TO/i:{\
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ 6c[Slq!KA
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ
ZE[NQ8
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì 's\rQ-TV
m}32ovpw
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ 49tJ+J- N
ufB9\yl{~
:/\KVz'fw}
רҵ¿Î ÃâÒßѧ R
q
.2
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê ~sVbg$]\ G
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell v`\ CzT
5. Fc¦Å receptor 6. Cytokine #Fckev4
¶þ¡¢ ÎÊ´ðÌâ /}Ct2w&<k
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 *],=!
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ l9+)h}
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ @@5JuI-!
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 q
rF:=?`E
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠ&\W5|*`x-
$AF,4Ir-b+
F#Bi*YY
d(q2gd@
yHs'E4V`$
F-<c.
0;6
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ *n`8 -=
^)1!TewCY
rW[7
_4
רҵ¿Î ÃâÒßѧ RJE<1!{
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê kj@m5`G
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen /'L/O;H20
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin fvM|Jb
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test }b/G{92
9. Hybridoma technic 10.Mitogen *W<|5<<u@
11.Dentritic cell 12.Immunoproliferation $`txU5#vs
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ k7=mxXF
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ ktiC*|fd
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦ÓᣠOs)}kkja
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ .!Os'Y9[,
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ vLQh r&I
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ F2CoXe7
3t$)saQR
K ZQ
`
fMIKA72>{
QE~#eo
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ K*oWcsu
<m+$@:cO
-\~D6OA
רҵ¿Î ÃâÒßѧ n##d!d|g
Ò»¡¢ Ãû´Ê½âÊÍ Hbi2amfBu
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï Pt8 U0)i)
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà 5Y(f7,JX
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ ccJ!N
¶þ¡¢ ÎÊ´ðÌâ qy:
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ Wf:I
0
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ |T^c(RpOE
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ i*Ee(m]I
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ 9Sk?tl
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ Mwd(?o
gTwxmp.,
Oa|'wh ug
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ i-_ * 5%A
9?#L/
RNn5,W
רҵ¿Î ÃâÒßѧ q/HwcX+[b
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê nnPY8pdjSD
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR XB'PEvh8
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA
Zqnwf
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM m6oaO9"K
¶þ¡¢ ÎÊ´ðÌâ }Pn]j7u!
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ e4/Y/:vFO
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ 9akIu.H
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ D!d1%hac
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ t\%gP@?
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ zwa%$U
>2w^dI2
5x:dhkW
I?_YL*
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ nVt,= ?_ U
$'obj
^$I8ga
רҵ¿Î ÃâÒßѧ X|w[:[P
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê w( ^
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule K-CF5i:
5. Autogous mixed lymphoyte reaction k6?;D_dm
¶þ¡¢ ÎÊ´ðÌâ vRQ7=N{3
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ gL:Vj%c
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ shAoib?Kw:
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ%P2l@}?a
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ q&RezHK l
T
7bDt
rV0X*[]J>
'M'k$G@Z
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ <X b B;
X
DdF7i}
~0 Ifg_G
רҵ¿Î ÃâÒßѧ PV\aQO.mo
;qN;oSK
4{rqGC/
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 7B)m/%>3s
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance Ump$N#
5. Delayed type hypersensitivity ;LXwW(_6d
¶þ¡¢ ÎÊ´ðÌâ '=X)0GG
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ nign"r
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ o<8('j
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ ;[-TsX:
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ(& UQ^
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠd^(7\lw
|
rV_i|
x=M%QFe
<c77GimD?
JJZu%9~[
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ @y!oKF
ZO#f)>s2
F(?O7z"d
רҵ¿Î ÃâÒßѧ 2Wn*J[5
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê \]8F_K
1. hypersensitivity 2. cluster of differentiation ~jR4%VF
3. adhesion molecules 4. supper antigen 5. split tolerance d@XXqCR<
¶þ¡¢ ÎÊ´ðÌâ Fd86P.Df
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ { MV,>T_
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ Kcvst
C`
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ gHo sPY[
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ 5MCnGg@
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ %vil~NU
jQrj3*V
`y|_hb
SF=TG84<
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ
&,l(2z[
רҵ¿Î ÃâÒßѧ "g,`K s ];
Ò»¡¢ Ãû´Ê½âÊÍ mCyn:+
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å "ze-Mb
5. GVHR @y'0_Y0-B
¶þ¡¢ ÎÊ´ðÌâ >qz#&